

Four New Dibenzocyclooctene Lignans from *Kadsura renchangiana*

by Min Chen, Zhixin Liao, and Daofeng Chen*

Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 200032,
People's Republic of China
(phone: +86-21-54237453; fax: +86-21-64042268; e-mail: dfchen@shmu.edu.cn)

Four new dibenzocyclooctene-type lignans, named renchangianins A–D (**1**–**4**), were isolated from the stems of *Kadsura renchangiana*. Their structures and configurations were elucidated by spectroscopic methods, including 2D-NMR techniques. Renchangianin D (**4**) possesses a spiro[dibenzocyclooctene-6,2'-oxirane] parent structure previously unknown in plants of the Schisandraceae family.

Introduction. – The stems or roots of *Kadsura* plants are commonly used in China as the folk medicines for treatment of rheumatic arthritis, traumatic injury, gastric and duodenal ulcer, dysmenorrhea, abdominal pain, and related diseases [1]. Lignans, especially of the dibenzocyclooctene type, are the principal bioactive constituents of *Kadsura* medicinal plants. Pharmacological studies have revealed various beneficial activities, including antitumor, antiviral, antihepatotoxic, and antioxidant effects either of the crude extracts or of isolated constituents from *Kadsura* plants [2] [3]. In previous studies, we had isolated several new dibenzocyclooctene lignans from *Kadsura interior* and *K. heteroclita* [4] [5], and their various biological activities such as antitumor-promoting effects, calcium antagonism, anti-lipid peroxidation, and anti-HIV effects were reported [6–10]. In our continuing efforts to search for new bioactive natural products from *Kadsura* medicinal plants, chemical investigation of the stems of *Kadsura renchangiana*, indigenous mainly to South China, now led to the isolation and identification of four new dibenzo[*a,c*]cyclooctene lignans named renchangianins A–D (**1**–**4**). This paper deals with the isolation and characterization of the new compounds.

Results and Discussion. – Repeated column chromatography (CC) of the Et₂O extract of the stems of *Kadsura renchangiana* yielded renchangianins A–D (**1**–**4**). Renchangianin A (**1**), obtained as colorless needles, had the molecular formula C₃₁H₃₄O₁₁, as determined by HR-ESI-MS (*m/z* 605.1983 ([*M*+Na]⁺). The UV spectrum of **1**, with a maximum absorption at 222 nm and two shoulders at 274 and 284 nm, respectively, along with the corresponding ¹H- and ¹³C-NMR spectra (Tables 1 and 2, resp.) indicated that **1** was a dibenzocyclooctene-type lignan [11].

The ¹H-NMR spectrum of **1** (Table 1) showed a *singlet* at δ_H 1.38 (Me–C(6)) and a *doublet* at δ_H 1.27 (*J* = 7.1 Hz, Me–C(7)), the latter indicating the presence of a Me group attached to a tertiary, OH-bearing (δ_H 2.13 (br. *s*)) C-atom. In the HMBC spectrum of **1** (Fig. 1), the resonance at δ_H 5.96 (*s*, H–C(5)) correlated with the C-atoms at δ_C 42.9 (C(7)), 74.2 (C(6)), and 28.8 (Me–C(6)), and the resonance at δ_H 5.74





Table 1. 400 MHz ¹H-NMR Data of **1–4**. In CDCl₃ at 27°; δ in ppm, *J* in Hz. Abbreviations: Ac, acetyl; Ang, angeloyl; Bz, benzoyl; Cin, cinnamoyl.

	1	2	3	4
H–C(4)	6.72 (s)	6.71 (s)	6.55 (s)	6.48 (s)
H _α –C(5)	5.96 (s)	5.97 (s)	5.97 (<i>d</i> , <i>J</i> = 7.6)	5.54 (s)
H–C(6)	–	–	2.22 (<i>m</i>)	–
H–C(7)	2.38 (<i>q</i> , <i>J</i> = 7.2)	2.43 (<i>q</i> , <i>J</i> = 7.2)	2.38 (<i>m</i>)	3.07 (<i>q</i> , <i>J</i> = 7.2)
H _β –C(8)	5.74 (s)	5.76 (s)	5.76 (s)	5.77 (s)
H–C(9)	6.79 (s)	6.83 (s)	6.79 (s)	6.91 (s)
Me–C(6)	1.38 (s)	1.36 (s)	0.99 (<i>d</i> , <i>J</i> = 7.1)	–
Me–C(7)	1.27 (<i>d</i> , <i>J</i> = 7.1)	1.38 (<i>d</i> , <i>J</i> = 7.2)	1.26 (<i>d</i> , <i>J</i> = 7.1)	1.04 (<i>d</i> , <i>J</i> = 7.2)
2-MeO	3.93 (s)	3.87 (s)	3.87 (s)	3.87 (s)
3-MeO	3.96 (s)	3.95 (s)	3.90 (s)	3.91 (s)
10-MeO	3.25 (s)	3.21 (s)	3.77 (s)	–
11-MeO	3.24 (s)	3.32 (s)	3.53 (s)	3.34 (s)
12-MeO	–	–	–	3.19 (s)
6-OH	2.13 (br. s)	2.35 (br. s)	–	–
1-OH	5.78 (br. s)	6.49 (br. s)	5.54 (br. s)	5.76 (br. s)
10-OH	–	–	–	5.52 (br. s)
12-OH	5.85 (br. s)	7.27 (br. s)	5.90 (br. s)	–
Ac	1.60 (s, 3 H)	–	–	–
CH ₂ (3')	–	–	–	2.94/2.92 (<i>AB</i> , <i>J</i> ≈ 3.6, 2 H)
Bz ^a):				
H–C(3',7')	7.42 (<i>d</i> , <i>J</i> = 7.6)	7.42 (<i>d</i> , <i>J</i> = 7.2)	–	7.45 (<i>d</i> , <i>J</i> = 7.5)
H–C(4',6')	7.28 (<i>t</i> , <i>J</i> = 7.5)	7.26 (<i>t</i> , <i>J</i> = 7.7)	–	7.29 (<i>t</i> , <i>J</i> = 7.7)
H–C(5')	7.49 (<i>t</i> , <i>J</i> = 7.3)	7.49 (<i>d</i> , <i>J</i> = 7.2)	–	7.46 (<i>m</i>)
Cin:				
H–C(2')	–	–	6.03 (<i>d</i> , <i>J</i> = 16.0)	–
H–C(3')	–	–	7.15 (<i>d</i> , <i>J</i> = 16.0)	–
H–C(5',9')	–	–	7.40 (<i>m</i>)	–
H–C(6',7',8')	–	–	7.34 (<i>m</i>)	–
Ang ^b):				
H–C(3'')	–	5.97 (<i>m</i>)	5.87 (<i>dq</i> , <i>J</i> = 7.2, 1.2)	5.94 (<i>dq</i> , <i>J</i> = 7.2, 1.2)
Me(4'')	–	1.90 (<i>d</i> , <i>J</i> = 7.2)	1.87 (<i>d</i> , <i>J</i> = 7.2)	1.87 (<i>dd</i> , <i>J</i> = 7.2, 1.3)
Me(5'')	–	1.32 (s)	1.34 (s)	1.30 (s)

^a) Doubly primed atom numbering for the Bz group in **4** (see chemical formulae). ^b) Triply primed atom numbering for the Ang group in **4**.

HMQC correlation, suggested the presence of two additional OH groups on the aromatic rings, as confirmed by IR (bands at 3563 and 3427 cm^{–1}). Considering the positions of the MeO groups, the two aromatic OH groups were located at C(1) and C(12), as corroborated by NOESY correlations between the 2-MeO and the 1-OH group (δ_H 5.78 (br. s, 1 H)), and between the 11-MeO and the 12-OH group (δ_H 5.85 (br. s, 1 H)) (Fig. 1).

In the EI mass spectrum, the peaks at *m/z* 522 ([*M* – AcO]⁺), 400 [*M* – C₆H₅COOH – AcO]⁺, and 105 ([C₆H₅CO]⁺) suggested the presence of an acetyl (Ac) and a benzoyl (Bz) group, as confirmed by ¹H-NMR resonances at δ_H 1.60 (s, Ac) and δ_H 7.42 (*d*, 2 H of Bz), 7.28 (*t*, 2 H of Bz), and 7.49 (*t*, 1 H of Bz), along with the corresponding Ac ¹³C-NMR signals (δ_C 168.8 and 20.1) and the C=O resonance of the Bz group (δ_C 164.8). The HMBC correlations of δ_H 5.74 (H–C(8)) with δ_C 168.8

Fig. 1. Key HMBC and NOESY correlations observed for compound **1**Table 2. 100 MHz ^{13}C -NMR Data of **1**–**4**. In CDCl_3 at 27° ; δ in ppm. Abbreviations: Ac, acetyl; Ang, angeloyl; Bz, benzoyl; Cin, cinnamoyl.

	1	2	3	4		1	2	3	4
C(1)	146.9	147.1	147.5	147.6	Bz ^a):				
C(2)	135.2	135.4	135.2	135.5	C(1')	164.8	164.8	–	164.6
C(3)	150.6	150.7	150.6	151.3	C(2')	129.0	129.5	–	129.6
C(4)	107.7	107.8	107.2	105.4	C(3',7')	129.5	128.1	–	129.2
C(4a)	129.8	129.7	131.1	130.7	C(4',6')	128.1	129.1	–	128.1
C(5)	85.0	85.2	80.8	84.3	C(5')	133.3	133.2	–	133.2
C(6)	74.2	74.2	38.8	60.4					
C(7)	42.9	43.1	38.8	37.5	Cin:				
C(8)	83.6	83.7	80.8	80.0	C(1')	–	–	165.6	–
C(8a)	135.4	135.8	136.2	135.6	C(2')	–	–	117.9	–
C(9)	109.9	109.6	110.2	109.7	C(3')	–	–	144.6	–
C(10)	149.5	149.4	148.9	149.5	C(4')	–	–	134.1	–
C(11)	138.7	138.6	138.8	138.9	C(5',9')	–	–	128.8	–
C(12)	149.4	147.1	148.9	150.1	C(6',8')	–	–	130.3	–
C(12a)	118.5	118.7	119.6	118.2	C(7')	–	–	127.9	–
C(12b)	115.9	115.9	116.3	115.5					
6-Me	28.8	28.8	15.7	–	Ang ^b):				
7-Me	17.1	17.3	20.5	14.9	C(1'')	–	165.2	166.8	166.1
2-MeO	60.7	59.7	60.4	60.4	C(2'')	–	125.6	127.1	126.6
3-MeO	55.9	55.9	55.9	55.9	C(3'')	–	141.6	139.4	140.4
10-MeO	59.6	60.4	60.6	–	Me(4'')	–	15.8	15.7	15.6
11-MeO	59.8	59.5	60.1	59.7	Me(5'')	–	19.9	20.3	19.8
12-MeO	–	–	–	59.7					
C(3')	–	–	–	47.3	Ac:				
					MeC=O	20.1			
					MeC=O	168.8	–	–	–

^a) Doubly primed atom numbering for the Bz group in **4** (see chemical formulae). ^b) Triply primed atom numbering for the Ang group in **4**.

(MeCO), of δ_{H} 1.60 (Ac) with δ_{C} 168.8, of δ_{H} 5.96 (H–C(5)) with δ_{C} 164.8 (PhCO), and of δ_{H} 7.42 (2 H of Bz) with δ_{C} 164.8 (PhCO) revealed that the AcO and BzO groups were located at C(8) and C(5), respectively. These assignments were further confirmed by NOESY cross-peaks of H–C(8) (δ_{H} 5.74) with H–C(9) (δ_{H} 6.79), and of H–C(5) (δ_{H} 5.96) with H–C(4) (δ_{H} 6.72) (see Fig. 1).

The circular dichroism (CD) spectrum of **1** showed negative and positive *Cotton* effects at 237 and 220 nm, respectively, indicating that **1** contains an axially chiral (aS)-1,1'-biphenyl unit ((*P*)-helicity) [6]. The substituent positions and stereochemical assignments were strengthened by NOESY correlations between H–C(4) and 3-MeO, H–C(4) and H $_{\alpha}$ –C(5), H $_{\alpha}$ –C(5) and both Me–C(6) and 6-OH, H–C(9) and H $_{\beta}$ –C(8), H $_{\beta}$ –C(8) and both Me–C(7) and H–C(7), H–C(4) and 6-OH, 6-OH and Me–C(7), as well as between Me–C(6) and H–C(7). Further, the NOESY correlations between H–C(4) and H $_{\alpha}$ –C(5), Me–C(7) and H–C(8), as well as between H–C(8) and H–C(9) indicated a twist-boat-chair (TBC) conformation for the dibenzocyclooctene ring (Fig. 1) [12].

Based on the above considerations – and after simulating the structure of **1** by means of computer modeling (Fig. 2), giving rise to a conformation that was in accord with the observed NOESY spectrum – the structure of renchangianin A (**1**) was determined as ((a*R*,5*S*,6*S*,7*S*,8*R*)-8-acetoxy-5,6,7,8-tetrahydro-1,6,12-trihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyldibenzo[*a,c*]cycloocten-5-yl) benzenecarboxylate.




Fig. 2. 3D Structure of renchangianin A (**1**) generated by computer modeling (see Exper. Part)

Renchangianin B (**2**) was obtained as a colorless powder. Its molecular formula was determined as C₃₄H₃₈O₁₁ by HR-ESI-MS (m/z 645.2304 ([*M* + Na]⁺)). The UV and NMR spectra revealed that **2** had a C₁₈-lignan skeleton, with two OH groups and four MeO groups. Its IR, UV, CD, and NMR data were similar to those of **1**. Comparison of the NMR spectra of **2** with those of **1** (Tables 1 and 2) indicated that the Ac group in **1**

was replaced by an angeloyl (Ang; =2-methylbut-2-enoyl) group in **2** [δ_{H} 5.97 (*m*, 1 H), 1.90 (*d*, $J = 7.2$ Hz, 3 H), 1.32 (*s*, 3 H); δ_{C} 165.2, 125.6, 141.6, 15.8, 19.9]. The presence of an Ang group was confirmed by EI-MS, which showed signals at m/z 522 ($[M - \text{C}_4\text{H}_7\text{COOH}]^+$), 83 ($\text{C}_4\text{H}_7\text{CO}^+$), and 55 (C_4H_7^+). The Ang group was attached at C(8), as deduced from the HMBC correlations of δ_{H} 5.76 (H–C(8)) with the Ang C=O signal at δ_{C} 165.2, and of H–C(8) with δ_{C} 135.8 (C(8a)), 109.6 (C(9)), 118.7 (C(12a)), 74.2 (C(6)), 43.1 (C(7)), and 17.3 (Me–C(7)). Based on CD and NOESY data, the configuration of **2** was determined to be the same as that of **1**. Thus, the structure of renchangianin B was elucidated as ((*aR*,5*S*,6*S*,7*S*,8*R*)-5,6,7,8,-tetrahydro-1,6,12-trihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyl-8-(((*Z*)-2-methylbut-2-enoyl)-oxy)dibenzo[*a,c*]cycloocten-5-yl) benzenecarboxylate.

Renchangianin C (**3**) was obtained as a yellow powder. Its molecular formula was determined as $\text{C}_{36}\text{H}_{40}\text{O}_{10}$ based on HR-ESI-MS (m/z 655.2515 ($[M + \text{Na}]^+$)). Its IR, UV, CD, and NMR data were similar to those of **2**. The structural differences between **3** and **2** were the lack of the 7-OH group in **3** relative to **2**, and the replacement of the Bz group of **2** by a cinnamoyl (Cin) group in **3**.

In the dibenzocyclooctene ring of **3**, the two signals at δ_{H} 1.26 and 0.99 (2*d*, $J = 7.1$ Hz each) were assigned to the *cis*-oriented [15] Me–C(7) and Me–C(6) groups, respectively. A cinnamoyl (Cin) and an angeloyl (Ang) group were identified by EI-MS, with signals at m/z 484 ($[M - \text{C}_6\text{H}_5\text{C}_2\text{H}_2\text{COOH}]^+$), 147 ($\text{C}_6\text{H}_5\text{C}_2\text{H}_2\text{COOH}^+$), 131 ($\text{C}_6\text{H}_5\text{C}_2\text{H}_2\text{CO}^+$), 103 ($\text{C}_6\text{H}_5\text{C}_2\text{H}_2^+$); and at 532 ($[M - \text{C}_4\text{H}_7\text{COOH}]^+$), 83 ($\text{C}_4\text{H}_7\text{CO}^+$), and 55 (C_4H_7^+), respectively. This was corroborated by ^1H -NMR, with Cin signals at δ_{H} 6.03, 7.15 (2*d*, $J = 16.0$ Hz, 1 H each), 7.34–7.40 (*m*, Ph), and with Ang signals at δ_{H} 5.87 (*dq*, $J = 7.2$, 1.2 Hz, 1 H), 1.87 (*d*, $J = 7.2$ Hz, 3 H), and 1.34 (*s*, 3 H). The HMBC spectrum of **3** clearly showed correlations of the resonance at δ_{H} 5.97 (H–C(5)) with the Cin C=O C-atom at δ_{C} 165.6, and of the H-atom at δ_{H} 5.76 (H–C(8)) with the Ang C=O resonance at δ_{C} 166.8, which revealed that the Cin and Ang groups were located at C(5) and C(8), respectively.

The CD spectrum of **3** indicated an axially chiral (*aS*)-1,1'-biphenyl unit (negative and positive Cotton effects at 250 and 218 nm, resp.). The stereochemical assignments were deduced by the following NOESY correlations (Fig. 3): H–C(4)/3-MeO, H–C(4)/ H_α –C(5), Me–C(6)/ H_α –C(5), Me–C(5)/H–C(4), H_α –C(5)/H–C(6), H–C(9)/ H_β –C(8), H_β –C(8)/H–C(7), H_β –C(8)/Me–C(7), H–C(6)/Me–C(7), and H–C(7)/Me–C(6). The NOESY correlations between H–C(4)/ H_α –C(5), Me–C(7)/H–C(8), and H–C(8)/H–C(9) indicated a TBC conformation of the fused cyclooctane ring. Thus, the structure of **3** was identified as ((*aR*,5*R*,6*S*,7*R*,8*R*)-5,6,7,8-tetrahydro-1,12-dihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyl-1-5-(((*E*)-3-phenylprop-2-enoyl)oxy)dibenzo[*a,c*]cycloocten-8-yl) (*Z*)-2-methylbut-2-enoate.

Renchangianin D (**4**) was obtained as a brown powder. HR-ESI-MS gave rise to a quasi-molecular ion at 643.2153 ($[M + \text{Na}]^+$), indicating a molecular formula of $\text{C}_{34}\text{H}_{36}\text{O}_{11}$. The IR, CD, and NMR spectra revealed a dibenzocyclooctene-lignan skeleton, with oxygenated C(5)- and C(8)-atoms, as in **1–3**. However, in **4**, a different substitution pattern of the aromatic rings and an additional spirocyclic epoxy system were identified, the spiro center being at C(6)).

The ^1H -NMR spectrum of **4** showed two aromatic signals at δ_{H} 6.48 and 6.91 (2*s*, 1 H each), four MeO groups at δ_{C} 3.91, 3.87, 3.34, and 3.19 (4*s*) on two aromatic rings. The




Fig. 3. Key NOESY correlations observed for compound **3**

absence of a typical OCH_2O ^{13}C -NMR signal at δ_{C} 100–102 (Table 2), and the presence of two ^1H -NMR signals at δ_{H} 5.76, 5.52 (2 br. s, 1 H each), lacking any HMQC correlation, suggested the presence of two OH groups on the aromatic rings, as confirmed by IR (3519, 3421 cm^{-1}). HMBC Cross-peaks of the above four MeO groups (δ_{H} 3.87, 3.91, 3.34, 3.19) with δ_{C} 135.5 (C(2)), 151.3 (C(3)), 138.9 (C(11)), and 150.1 (C(12)), respectively, revealed that one OH group was at C(10) (δ_{C} 149.5), as confirmed by an NOE correlation between the 11- and 12-MeO groups. In the ^{13}C -NMR spectrum of **4**, C(6) at δ_{C} 60.4 was identified as an oxygenated quaternary center by means of an HMQC experiment. By comparing the ^1H -NMR spectra of **4** and **2**, it was found that the Me–C(6) resonance at δ_{H} 1.36 (s, 3 H) in **2** was replaced by a methylene signal at δ_{H} 2.94, 2.92 (AB, $J \approx 3.6$ Hz) in **4** (Table 1), the corresponding ^{13}C -NMR signal (C(3')) being found at δ_{C} 47.3, as assigned by the HMQC spectrum.

The extra degree of unsaturation of **4** relative to **2** suggested an additional ring system. Based on the information provided by ^1H - and ^{13}C -NMR, it was suggested that **4** contained a spirocyclic epoxy system, similar to both the valtrate-type iridoids in *Valeriana jatamansi* [16] and juncins I–M from *Junceella juncea* [17]. The ^1H -NMR data [δ_{H} 2.94, 2.92 (AB, $J \approx 3.6$ Hz, $\text{CH}_2(3')$)] and ^{13}C -NMR data [δ_{C} 60.4 (C(6)), 47.3 (C(3'))] of **4** matched those of the corresponding epoxide system in 1-homoisoacevaltrate [δ_{H} 2.91, 3.02 (AB, $J \approx 5.0$ Hz; δ_{C} 64.2, 48.0]. The HMBC correlations of $\text{CH}_2(3')$ with C(6), and of H–C(7) at δ_{H} 3.07 (d, $J = 7.2$ Hz) with $\text{CH}_2(3')$ and C(6) confirmed that the $\text{CH}_2(3')$ epoxy methylene group was connected with C(6) (Fig. 4). This is the first time to find a lignan with a novel three-membered ether ring in the plants of the Schisandraceae family.

The CD spectrum of **4** again indicated an (aS)-1,1'-biphenyl unit, with negative and positive Cotton effects at 239 and 218 nm, respectively. The substituent positions and stereochemical assignments were strengthened by the following NOESY correlations: H–C(4)/3-MeO, H–C(4)/ H_{α} -C(5), H_{α} -C(5)/ $\text{CH}_2(3')$, H–C(9)/ H_{β} -C(8), and H_{β} -C(8)/H–C(7). The correlations of $\text{CH}_2(3')$ with H–C(4), H_{α} -C(5) and Me–C(7) in the NOESY spectrum indicated that $\text{CH}_2(3')$ was α -oriented with respect to the fused cyclooctane ring. Cross-peaks between H–C(4)/ H_{α} -C(5), Me–C(7)/H–C(8), and H–C(8)/H–C(9) in the NOESY spectrum further revealed a TBC




Fig. 4. Key HMBC and NOESY correlations observed for compound **4**

conformation of the cyclooctane ring. Thus, the structure of **4** was determined as (a*R*,5*S*,6*S*,7*S*,8*R*)-5-[(benzoyl)oxy]-2',3',5,6,7,8,-hexahydro-1,10-dihydroxy-2,3,11,12-tetramethoxy-7-methyl-8-[(*Z*)-2-methylbut-2-enoyl]oxy]spiro[dibenzo[*a,c*]cyclooctene-6,2'-oxirane].

This investigation was supported, in part, by grants from the *National Natural Science Foundation of China* (30271586), the *Foundation for the Doctoral Programs* (2000026519), the *Trans-Century Training Program Foundation for the Talents*, and the *Teaching and Research Award Program for Outstanding Young Teachers in Higher Education Institutions* (1999-71) from the *Ministry of Education*, P.R. China. The authors wish to thank Prof. Deyong Ye and Xiangqing Jiang at Fudan University for creating the 3D picture.

Experimental Part

General. Anal. TLC was performed on silica-gel plates (*Yan-tai Institute of Chemical Technology*), with petroleum ether/AcOEt 3:1 as eluent; visualization under UV light and by spraying with 10% aq. H₂SO₄, followed by heating. Column chromatography (CC): silica gel (100–200, 200–300, or 300–400 mesh; *Qingdao Marine Chemical Factory*). Melting points (m.p.): *XT-4* micromelting point apparatus (*Tai-Ke Instrument Co.*, Beijing, China); uncorrected. Optical rotations (ORD): *JASCO P-1020* spectropolarimeter. UV Spectra: *Shimadzu UV-260* spectrophotometer, in anhyd. MeOH; λ_{\max} in nm (log ϵ). CD Spectra: *JASCO J-715* spectropolarimeter. IR Spectra: *Avatar 360 E.S.P.* spectrophotometer (*Thermo Nicolet*), as KBr pellets; in cm⁻¹. ¹H- and ¹³C-NMR Spectra: *Bruker AV-500* or *DRX-400* spectrometers, in CDCl₃, δ in ppm rel. to SiMe₄ (=0 ppm), *J* in Hz. EI-MS: *HP-5989A* mass spectrometer, in *m/z*. HR-ESI-MS: *APEX 7.0 TESLA FT-MS* apparatus. Computer modeling (see Fig. 2) was performed with the SYBYL (v. 6.9) software on a *Silicon Graphics* workstation. The structure was simulated annealing and optimized subsequently with the *Tripos* force-field energy-minimizing program.

Plant Material. The stems of *Kadsura renchangiana* were collected in Long-sheng County, Guang-xi autonomous region, P.R. China, in November 1997. A voucher specimen (DFC-XT9701) was deposited at the Herbarium of Materia Medica, Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai, P.R. China.

Extraction and Isolation. The air-dried stems (10 kg) of *K. renchangiana* were ground and extracted exhaustively with 95% aq. EtOH at r.t. The EtOH extract was evaporated *in vacuo* to yield a semi-solid (650 g), which was suspended in H₂O (1000 ml) and extracted with Et₂O (7 × 350 ml). The resulting ethereal soln. was concentrated to yield a residue (190 g), which was purified by CC (2.2 kg SiO₂; petroleum ether/AcOEt mixtures of increasing polarity), giving rise to several fractions (Fr.). Fr.8, eluted with petroleum ether/AcOEt 7:3, afforded **1** (150 mg). Fr.9 (petroleum ether/AcOEt 6:4) was subjected to repeated CC (SiO₂; petroleum

ether/AcOEt 3:1) to yield **2** (13 mg) and **3** (68 mg). *Fr.7* (petroleum ether/AcOEt 8:2) was subjected to repeated CC (SiO₂; petroleum ether/AcOEt 3:1) to yield **4** (25 mg).

((*aR*,5*S*,6*S*,7*S*,8*R*)-8-Acetoxy-5,6,7,8,-tetrahydro-1,6,12-trihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyldibenzo[a,c]cycloocten-5-yl) Benzenecarboxylate (*renchangianin A*; **1**). Colorless needles (MeOH). M.p. 231–232°. $[\alpha]_D^{25} = -177.9$ ($c = 0.89$, MeOH). UV (MeOH): 222 (4.11), 274 (sh, 3.14), 284 (sh, 3.15). CD ($c = 0.05$, MeOH): $\Delta\epsilon_{204} = -11$, $\Delta\epsilon_{220} = +23$, $\Delta\epsilon_{237} = -60.5$. IR (KBr): 3563, 3427, 1746, 1720, 1587, 1494, 1456, 736, 713. ¹H- and ¹³C-NMR: see *Tables 1* and *2*, resp. EI-MS: 582 (5, *M*⁺), 522 (61), 451 (37), 400 (14), 357 (76), 105 (100), 77 (23). HR-ESI-MS: 605.1983 ($[M + Na]^+$, C₃₁H₃₄NaO₁₁⁺; calc. 605.1999).

((*aR*,5*S*,6*S*,7*S*,8*R*)-5,6,7,8,-Tetrahydro-1,6,12-trihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyl-8-[(*(Z)*-2-methylbut-2-enoyl)oxy]dibenzo[a,c]cycloocten-5-yl) Benzenecarboxylate (*renchangianin B*; **2**). Colorless powder. $[\alpha]_D^{25} = -136.1$ ($c = 0.31$, MeOH). UV (MeOH): 226 (4.24), 273 (sh, 3.29), 283 (sh, 3.29). CD ($c = 0.05$, MeOH): $\Delta\epsilon_{215} = +43$, $\Delta\epsilon_{252} = -37$. IR (KBr): 3417, 1729, 1415, 1382, 1265, 738. ¹H- and ¹³C-NMR: see *Tables 1* and *2*, resp. EI-MS: 622 (2, *M*⁺), 522 (37), 450 (19), 400 (9), 357 (47), 105 (100), 83 (25), 77 (23), 55 (33). HR-ESI-MS: 645.2304 ($[M + Na]^+$, C₃₄H₃₈NaO₁₁⁺; calc. 645.2312).

((*aR*,5*R*,6*S*,7*R*,8*R*)-5,6,7,8-Tetrahydro-1,12-dihydroxy-2,3,10,11-tetramethoxy-6,7-dimethyl-5-[(*(E)*-3-phenylprop-2-enoyl)oxy]dibenzo[a,c]cycloocten-8-yl) (*Z*)-2-methylbut-2-enoate (*renchangianin C*; **3**). Yellow powder. $[\alpha]_D^{25} = +50.4$ ($c = 1.09$, MeOH). UV (MeOH): 222 (3.90), 254 (3.48), 275 (3.52). CD ($c = 0.05$, MeOH): $\Delta\epsilon_{218} = +25$, $\Delta\epsilon_{250} = -21$. IR (KBr): 3428, 1705, 1637, 1585, 1494, 1455, 736. ¹H- and ¹³C-NMR: see *Tables 1* and *2*, resp. EI-MS: 632 (9, *M*⁺), 532 (9), 501 (11), 484 (3), 402 (16), 384 (23), 370 (24), 353 (38), 147 (33), 131 (100), 103 (37), 83 (32), 77 (15). HR-ESI-MS: 655.2515 ($[M + Na]^+$, C₃₆H₄₀NaO₁₀⁺; calc. 655.2519).

((*aR*,5*S*,6*S*,7*S*,8*R*)-5-[(*Benzoyl*)oxy]-2',3',5,6,7,8,-hexahydro-1,10-dihydroxy-2,3,11,12-tetramethoxy-7-methyl-8-[(*(Z)*-2-methylbut-2-enoyl)oxy]spiro[dibenzo[a,c]cyclooctene-6,2'-oxirane] (*renchangianin D*; **4**). Brown powder. $[\alpha]_D^{25} = -14.7$ ($c = 0.65$, MeOH). UV (MeOH): 221 (3.99). CD ($c = 0.05$, MeOH): $\Delta\epsilon_{203} = -14$, $\Delta\epsilon_{218} = +13$, $\Delta\epsilon_{239} = -20$. IR (KBr): 3519, 3421, 1717, 1595, 1494, 1457, 738, 705. ¹H- and ¹³C-NMR: see *Tables 1* and *2*. EI-MS: 620 (34, *M*⁺), 520 (2), 498 (1), 489 (51), 398 (2), 383 (14), 367 (15), 339 (15), 325 (11), 105 (100), 83 (35), 77 (31), 55 (54). HR-ESI-MS: 643.2153 ($[M + Na]^+$, C₃₄H₃₆NaO₁₁⁺; calc. 643.2155).

REFERENCES

- [1] D. F. Chen, H. L. Peng, M. H. Jiang, D. W. Shi, *J. Shanghai Med. Univ.* **1996**, 23 (Suppl.), 52.
- [2] W. Z. Song, *Nat. Prod. Res. Dev.* **1991**, 3(1), 68.
- [3] Y. H. Kuo, S. Y. Li, M. D. Wu, R. L. Huang, H. C. Huang, K. H. Lee, *J. Nat. Prod.* **2001**, 64, 487.
- [4] D. F. Chen, S. X. Zhang, K. Chen, B. N. Zhou, P. Wang, L. M. Cosentino, K. H. Lee, *J. Nat. Prod.* **1996**, 59, 1066.
- [5] D. F. Chen, G. J. Xu, X. W. Yang, M. Hattori, Y. Tezuka, T. Kikuchi, T. Namba, *Phytochemistry* **1992**, 31, 629.
- [6] D. F. Chen, S. X. Zhang, M. Kozuka, Q. Z. Sun, J. Feng, Q. Wang, T. Mukainaka, Y. Nobukuni, H. Tokuda, H. Nishino, H. K. Wang, S. L. Morris-Natschke, K. H. Lee, *J. Nat. Prod.* **2002**, 65, 1242.
- [7] D. F. Chen, S. X. Zhang, L. Xie, J. X. Xie, K. Chen, Y. Kashiwada, B. N. Zhou, P. Wang, L. M. Cosentino, K. H. Lee, *Bioorg. Med. Chem.* **1997**, 5, 1715.
- [8] X. M. Zhang, D. F. Chen, X. J. He, S. Yang, P. Zheng, M. H. Jiang, *Acta Pharmacol. Sin.* **2000**, 21, 373.
- [9] H. L. Peng, D. F. Chen, H. X. Lan, X. M. Zhang, Z. Gu, M. H. Jiang, *Acta Pharmacol. Sin.* **1996**, 17, 538.
- [10] X. W. Yang, H. Miyashiro, M. Hattori, T. Namba, Y. Tezuka, T. Kikuchi, D. F. Chen, G. J. Xu, T. Hori, M. Extine, H. Mizuno, *Chem. Pharm. Bull.* **1992**, 40, 1510.
- [11] Y. Ikeya, H. Taguchi, I. Yosioka, H. Kobayashi, *Chem. Pharm. Bull.* **1979**, 27, 1384.
- [12] J. S. Liu, L. Li, *Phytochemistry* **1993**, 32, 1293.
- [13] Y. G. Chen, G. W. Qin, Y. Y. Xie, *Chin. J. Magn. Reson.* **2000**, 17, 427.
- [14] Y. Ikeya, H. Taguchi, H. Sasaki, K. Nakajima, I. Yosioka, *Chem. Pharm. Bull.* **1980**, 28, 2414.
- [15] Y. Y. Chen, Z. B. Shu, L. N. Li, *Scientia Sin.* **1976**, 19, 276.
- [16] Y. P. Tang, X. Liu, B. Yu, *J. Nat. Prod.* **2002**, 65, 1949.
- [17] A. S. R. Anjaneyulu, V. L. Rao, V. G. Sastry, M. J. R. V. Venugopal, F. J. Schmitz, *J. Nat. Prod.* **2003**, 66, 507.

Received January 8, 2004